Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics, is pleased to announce the official launch of its first-in-class predictive test for diabetic kidney disease, Promarker(R)D, in Australia.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) is pleased to announce the publication of results of its landmark study demonstrating the PromarkerD test significantly outperforms the current standard of care tests in predicting future kidney function decline.
Proteomics International Laboratories Ltd (Proteomics International; the Company; ASX:PIQ) (OTCMKTS:PIQLF) is proud to announce that it has opened its US Reference Laboratory and been awarded a Clinical Laboratory Improvement Amendment certificate of registration, as a certified clinical laboratory.
Memphasys Limited (ASX:MEM) (FRA:IG7) is pleased to announce successful completion of the data lock for the pivotal Felix(TM) clinical trial. This marks a critical milestone in ensuring the accuracy and integrity of the trial data.
Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in precision diagnostics, is pleased to release a copy of the presentation to be provided by Dr Richard Lipscombe to delegates at Euroz Hartleys 2025 Healthcare Forum being held on 4 February 2025.
Proteomics International Laboratories Ltd (ASX:PIQ) Managing Director Dr. Richard Lipscombe is Interviewed about the ProMarker Suite of Diagnostic Tests.
Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in precision diagnostics is pleased to provide the following update on its business activities for the three months to 31 December 2024.
